Clinical Year in Review: 2023

“This drug is already in phase 2 trials, and we look forward to more data in the near future,” he said.

Samantha C. Shapiro, MD, is the executive editor of Harrison’s Principles of Internal Medicine. As a clinician educator, she practices telerheumatology and writes for both medical and lay audiences.

References

1. Shapiro S. Clinical rheumatology year in review–2022. 2022 Dec 4. https://www.the-rheumatologist.org/article/clinical-rheumatology-year-in-review-2022/.
2. Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022 Jan;386(4)316–326.
3. Boers M, Hartman L, Opris-Belinski D, et al. Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial. Ann Rheum Dis. 2022 Jul;81:925–936.
4. Kristensen LE, Danese S, Yndestad A, et al. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: An analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 2023 Jul;82(7):901–910.
5. Almayali AAH, Boers M, Hartman L, et al. Tapering of long-term, low-dose glucocorticoids in senior rheumatoid arthritis patients: Follow-up of the pragmatic, multicentre, placebo-controlled GLORIA trial. Ann Rheum Dis. 2023 Oct;82(10):1307–1314.
6. Gill TK, Mittinty MM, March LM, et al. Global, regional, and national burden of other musculoskeletal disorders, 1990–2020, and projections to 2050: A systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023 Nov;5(11):e670–e682.
7. Steinmetz JD, Culbreth GT, Haile LM, et al. Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023 Aug;5(9):e508–e522.
8. Østergaard M, Van Vollenhoven RF, Rudin A, et al. Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial. Ann Rheum Dis. 2023 Oct;82(10):1286–1295.
9. Heijman MWJ, Fiolet ATL, Mosterd A, et al. Association of low-dose colchicine with incidence of knee and hip replacements: Exploratory analyses from a randomized, controlled, double-blind trial. Ann Intern Med. 2023 Jun;176(6):737–742.
10. Schieker M, Conaghan PG, Mindeholm L, et al. Effects of interleukin-1β inhibition on incident hip and knee replacement: Exploratory analyses from a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2020 Oct;173(7):509–515.
11. Tuttle J, Drescher E, Simón-Campos JA, et al. A phase 2 trial of peresolimab for adults with rheumatoid arthritis. N Engl J Med. 2023 May;388(20):1853–1862.
12. Buttgereit F, Aelion J, Rojkovich B, et al. Efficacy and safety of abbv-3373, a novel anti–tumor necrosis factor glucocorticoid receptor modulator antibody–drug conjugate, in adults with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: A randomized, double-blind, active-controlled proof-of-concept phase IIa trial. Arthritis Rheumatol. 2023 Jun;75(6):879–889.
13. Morand E, Pike M, Merrill JT, et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: A phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2023 Feb;75(2):242–252.
14. McInnes IB, Asahina A, Coates LC, et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: A randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet. 2023 Jan;401(10370):25–37.
15. Merola JF, Landewé R, McInnes IB, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: A randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet. 2023 Jan;401(10370):38–48.
16. Mease P, Helliwell P, Silwinska-Stanczyk P, et al. Efficacy and safety of the TYK2/JAK1 inhibitor brepocitinib for active psoriatic arthritis: A phase IIb randomized controlled trial. Arthritis Rheumatol. 2023 Aug;75(8):1370–1380.
17. Distler O, Allanore Y, Denton CP, et al. Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): Open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial. Lancet Rheumatol. 2023;5(11):e660–e669.
18. Petri M, Bruce IN, Dörner T, et al. Baricitinib for systemic lupus erythematosus: A double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet. 2023 Mar;401(10381):1011–1019.
19. Morand EF, Vital EM, Petri M, et al. Baricitinib for systemic lupus erythematosus: A double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet. 2023;401(10381):1011–1019.
20. Kaufman MB. FDA approves sarilumab for the treatment of glucocorticoid-resistant PMR. The Rheumatologist. 2023 Mar 14. https://www.the-rheumatologist.org/article/fda-approves-sarilumab-for-the-treatment-of-adults-with-glucocorticoid-resistant-pmr/#:~:text=On%20Feb.,cannot%20tolerate%20a%20glucocorticoid%20taper.&text=Sarilumab%20is%20an%20interleukin%20(IL)%206%20receptor%20antagonist.
21. Britanova OV, Lupyr KR, Staroverov DB, et al. Targeted depletion of TRBV9+ T cells as immunotherapy in a patient with ankylosing spondylitis. Nat Med. 2023 Oct 23. Online ahead of print.